1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AS2 Bio Inc

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Adiso Therapeutics

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aera Therapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Akttyva Therapeutics

Alamar Biosciences

Aldebaran Therapeutics

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Partner Therapeutics is developing therapeutics for cancer and other serious diseases like COVID-19.  Partner takes an innovative approach to therapeutic design by focusing on collaboration and partnership with leading companies, research centers and investigators to ensure products are rigorously tested. Partnering enables faster progress of treatment development programs to get effective therapies to patients sooner. Partner’s lead therapy is LEUKINE, the first and only FDA-approved granulocyte-macrophage colony-stimulating factor (GM-CSF). LEUKINE activates a multilineage immune defense against infection and has shown promising results in a Phase 3 clinical trial. Partner is also evaluating the efficacy of LEUKINE in patients with COVID-19 associated respiratory illness. 

<p>Partner Therapeutics is developing therapeutics for cancer and other serious diseases like COVID-19.  Partner takes an innovative approach to therapeutic design by focusing on collaboration and partnership with leading companies, research centers and investigators to ensure products are rigorously tested. Partnering enables faster progress of treatment development programs to get effective therapies to patients sooner. Partner’s lead therapy is LEUKINE, the first and only FDA-approved granulocyte-macrophage colony-stimulating factor (GM-CSF). LEUKINE activates a multilineage immune defense against infection and has shown promising results in a Phase 3 clinical trial. Partner is also evaluating the efficacy of LEUKINE in patients with COVID-19 associated respiratory illness. </p>


Find a biotech startup job.